TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31228593

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) of antagonist muscles plus single ES session on injected muscles
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single ES session on injected muscles alone
Number of subjects: 30
Study: 28094601

Group type: EXPERIMENTAL
Intervention: Patient navigator program (PAtient COach)
Number of subjects: 24
Study: 22538279

Group type: EXPERIMENTAL
Intervention: Side-alternating vibration (SV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Frequency (5-10-15-20-25-30 Hz)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Knee flexion angle (60°)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Forefoot stance condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Additional load (equal to one-third of body weight)
Number of subjects: 18
Study: 21787159

Group type: EXPERIMENTAL
Intervention: Synthetic high-flux dialyzer, polyethersulfone membrane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cellulose triacetate (CTA) high-flux membrane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Synthetic low-flux dialyzer, polymethylmethacrylate (PMMA) membrane
Number of subjects: 60
Study: 19549125

Group type: EXPERIMENTAL
Intervention: Population-based prostate-specific antigen (PSA) testing
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Population-based PSA testing
Number of subjects: 2022
Study: 16960930

Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg once daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Mizoribine 50 mg three times daily
Number of subjects: 204
Study: 15541832

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 990

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study: 11122885

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9516764

Group type: EXPERIMENTAL
Intervention: Group instruction
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Personal instruction
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 8372768

Group type: EXPERIMENTAL
Intervention: MR arthrography with 40-50 ml of a 1:100 solution of gadopentetate dimeglumine in saline
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional MR imaging
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MR arthrography
Number of subjects: 37

Group type: COMPARATOR
Intervention: Routine MR imaging
Number of subjects: 37
Study: 3534730

Group type: EXPERIMENTAL
Intervention: Cefoperazone 1 g IV every 8 hours for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cotrimoxazole 800 mg sulfamethoxazole and 160 mg trimethoprim every 12 hours for 5 days
Number of subjects: 60
Study: 30634046

Group type: EXPERIMENTAL
Intervention: Personalization methods in biomedical informatics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Design systems for eHealth applications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Design systems that collect data for treatment personalization
Number of subjects: 0
Study: 29424799

Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine (2 doses)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (1 dose of measles-mumps-rubella and diphtheria-tetanus-acellular-pertussis vaccines)
Number of subjects: 148
Study: 26666342

Group type: EXPERIMENTAL
Intervention: Procalcitonin ≥ 0.20 ng/mL (N=104)
Number of subjects: 1781

Group type: COMPARATOR
Intervention: Procalcitonin < 0.20 ng/mL
Number of subjects: 1781
Study: 24462855

Group type: COMPARATOR
Intervention: Systemic methotrexate (MTX)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Systemic methotrexate (MTX) combined with ultrasound-guided local injection of potassium chloride (KCl) or MTX
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Locally injected potassium chloride (KCl)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Locally injected methotrexate (MTX)
Number of subjects: 82
Study: 22626890

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Bup/Nal) for 12 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Buprenorphine/naloxone (Bup/Nal) for 2 weeks detoxification
Number of subjects: 152
Study: 20642545

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg (morning dosing)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg (evening dosing)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Evening dosing of Vildagliptin 100 mg
Number of subjects: 48
Study: 17715164

Group type: EXPERIMENTAL
Intervention: Inhalation of 100-125 ppm carbon monoxide (CO) for 2 hours per day over 4 consecutive days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract).
Number of subjects: 20
Study: 16248379

Group type: EXPERIMENTAL
Intervention: Takotsubo cardiomyopathy
Number of subjects: 14

Group type: COMPARATOR
Intervention: AMI
Number of subjects: 14
Study: 12065335

Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI), 300 mg bid
Number of subjects: 520

Group type: COMPARATOR
Intervention: Oral quinolone antibiotics (primarily ciprofloxacin)
Number of subjects: 520

Group type: COMPARATOR
Intervention: TSI therapy
Number of subjects: 520

Group type: COMPARATOR
Intervention: S maltophilia culture frequency
Number of subjects: 520
Study: 9537270

Group type: EXPERIMENTAL
Intervention: HbOC vaccine (3 doses at 2, 3, and 4 months of age)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (hepatitis B, OPV, and DPT without HbOC)
Number of subjects: 171
Study: 7616334

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Clonidine plus naltrexone
Number of subjects: 125
Study: 2523611

Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex), 3.6 mg sc/28 d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES), 1 mg tid
Number of subjects: 0
Study: 904400

Group type: EXPERIMENTAL
Intervention: Allergy evaluation using Rinkle and Lee techniques for inhalent and food allergies.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Challenge food tests administered to patients.
Number of subjects: 14
Study: 31937553

Group type: EXPERIMENTAL
Intervention: Active respiratory muscle training (RMT) performed twice daily for 6 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham respiratory muscle training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Active respiratory muscle training (RMT)
Number of subjects: 62
Study: 29982701

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (amisulpride, flupenthixol, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone) at adequate doses
Number of subjects: 6221
Study: 28294136

Group type: EXPERIMENTAL
Intervention: morphine (10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: naltrexone (50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 25807878

Group type: EXPERIMENTAL
Intervention: Image Integration Module (IIM, CartoUnivu™ Module)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional 3D mapping system (Carto® 3 System)
Number of subjects: 60
Study: 23865528

Group type: EXPERIMENTAL
Intervention: Community-based weight management program
Number of subjects: 349
Study: 21403042

Group type: EXPERIMENTAL
Intervention: Empowering Patients in Care (EPIC) intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Group education sessions with a DM educator and dietician
Number of subjects: 87
Study: 19494100

Group type: EXPERIMENTAL
Intervention: Home safety education with provision of safety equipment
Number of subjects: 0
Study: 16884050

Group type: EXPERIMENTAL
Intervention: Direct associations
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Related associations
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Strong associations (rated > 5)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Unrelated associations
Number of subjects: 63
Study: 15327447

Group type: EXPERIMENTAL
Intervention: Double-gloving method
Number of subjects: 300

Group type: COMPARATOR
Intervention: Single-gloving method
Number of subjects: 300

Group type: COMPARATOR
Intervention: Double-outer gloves
Number of subjects: 300
Study: 11249051

Group type: EXPERIMENTAL
Intervention: High-dose thiotepa (600 mg/m2) + melphalan (160 mg/m2) with hemopoietic support
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-dose thiotepa and melphalan
Number of subjects: 48
Study: 9623012

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22
Study: 7940765

Group type: EXPERIMENTAL
Intervention: CyA
Number of subjects: 59

Group type: COMPARATOR
Intervention: AzaP
Number of subjects: 59
Study: 3369327

Group type: EXPERIMENTAL
Intervention: Behavioral self-help booklets
Number of subjects: 304

Group type: COMPARATOR
Intervention: Factual information pamphlet (Control)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 304
Study: 29329169

Group type: EXPERIMENTAL
Intervention: PCV-10
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PCV-13
Number of subjects: 178
Study: 26173792

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 41

Group type: COMPARATOR
Intervention: Corticosteroid (CS) injection
Number of subjects: 41
Study: 26239087

Group type: EXPERIMENTAL
Intervention: bendamustine-rituximab (B-R)
Number of subjects: 173

Group type: COMPARATOR
Intervention: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Posttreatment Bcl-2/IgH status
Number of subjects: 173
Study: 22850489

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) combined with physical therapy modalities and joint mobilization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physical therapy modalities and passive joint mobilization of the shoulder (non-WBC group)
Number of subjects: 30
Study: 21118164

Group type: EXPERIMENTAL
Intervention: Ivabradine added to standard therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard treatment of SA and CHF
Number of subjects: 78
Study: 18708685

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16847937

Group type: EXPERIMENTAL
Intervention: Particulate only (P) filter
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Particulate/organic vapor (POV) filter
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Particulate/organic vapor/formaldehyde (POVF) filter
Number of subjects: 64
Study: 12920843

Group type: EXPERIMENTAL
Intervention: AT group
Number of subjects: 24

Group type: COMPARATOR
Intervention: non AT group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 10960460

Group type: EXPERIMENTAL
Intervention: Triple antiviral therapy (interferon alfa 5 megaunits on alternate days, ribavirin 800-1,000 mg daily, amantadine 200 mg daily) for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double therapy (interferon alfa 5 megaunits on alternate days, ribavirin 800-1,000 mg daily) for 12 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triple antiviral therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 60
Study: 8870441

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study: 2000817

Group type: EXPERIMENTAL
Intervention: Lard-modified formula
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unmodified formula
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 6342543

Group type: EXPERIMENTAL
Intervention: Standard treatment together with intrathecal equine antitetanus serum
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Intrathecal antitetanus serum with systemic betamethasone
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Parenteral intramuscular diazepam as a sedative
Number of subjects: 161

Group type: COMPARATOR
Intervention: Paraldehyde as a sedative
Number of subjects: 161
Study: 31350853

Group type: EXPERIMENTAL
Intervention: Experimental arm from randomized controlled trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EC-derived control arm
Number of subjects: 0
Study: 30924791

Group type: EXPERIMENTAL
Intervention: Accelerometry-based activity monitor (MyWellnessKey) and associated Web platform (MyWellnessCloud) plus usual practice (n=88)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual practice only (n=68)
Number of subjects: 156
Study: 30429941

Group type: EXPERIMENTAL
Intervention: Bundled HIV/HCV testing
Number of subjects: 478

Group type: COMPARATOR
Intervention: HIV testing alone
Number of subjects: 478
Study: 26370827

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Care (CGC)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Conventional Orthopaedic Care (OC)
Number of subjects: 397
Study: 25169631

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg, tid
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group treatment (low‐flow oxygen, low‐salt diet therapy, cardiac therapy)
Number of subjects: 64
Study: 23118406

Group type: EXPERIMENTAL
Intervention: Cryopneumatic device
Number of subjects: 280

Group type: COMPARATOR
Intervention: Ice with static compression
Number of subjects: 280
Study: 20709385

Group type: EXPERIMENTAL
Intervention: Sentences containing homophones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sentences without homophones
Number of subjects: 0
Study: 17409306

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) + usual care (n = 24)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care control only (n = 25)
Number of subjects: 49
Study: 16623032

Group type: EXPERIMENTAL
Intervention: High level of happiness (57.3%)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Extrovert personality, stable personality, high family income, improved marital relationship
Number of subjects: 438
Study: 16820805

Group type: EXPERIMENTAL
Intervention: HydraBrush Oral Health System (OHS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sonicare Elite 7800 (SE)
Number of subjects: 100
Study: 10937603

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pharmacotherapy (fluoxetine or bupropion)
Number of subjects: 75
Study: 8880051

Group type: EXPERIMENTAL
Intervention: 10 micrograms zacopride
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 400 micrograms zacopride
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 1520194

Group type: EXPERIMENTAL
Intervention: Wiped with dry cloth alone
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Put into a plastic bag immediately after birth
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Wiped with dry cloth and then inserted into a plastic bag
Number of subjects: 141
Study: 6840904

Group type: EXPERIMENTAL
Intervention: Desmethylimipramine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Drug-free period
Number of subjects: 16
Study: 30700278

Group type: EXPERIMENTAL
Intervention: Song of Life (SOL) music therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Relaxation exercises (control group)
Number of subjects: 104
Study: 30295329

Group type: EXPERIMENTAL
Intervention: Drawing-assisted interview
Number of subjects: 84

Group type: COMPARATOR
Intervention: Verbal cued-recall interview
Number of subjects: 84
Study: 27155189

Group type: COMPARATOR
Intervention: R10 (control regimen)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: R15 (Study Regimen 1)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: R20 (Study Regimen 2)
Number of subjects: 300
Study: 23789615

Group type: EXPERIMENTAL
Intervention: DVD and brochure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brochures only
Number of subjects: 0
Study: 22453248

Group type: EXPERIMENTAL
Intervention: oral glycerol = sports drink, water, and glycerol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IV = half as normal saline, half of sports drink, and water
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IV with oral glycerol = half as normal saline, half as sports drink, water, and glycerol
Number of subjects: 9

Group type: COMPARATOR
Intervention: oral = sports drink and water
Number of subjects: 9
Study: 20400004

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO(4)) infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control Group C)
Number of subjects: 60
Study: 17511361

Group type: EXPERIMENTAL
Intervention: Self-cure adhesive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of sandblasting with tribochemical silica coating
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 microm aluminum oxide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of sandblasting and tribochemical silica coating
Number of subjects: 60
Study: 16317826

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12162381

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO2) - 40 sessions over 2 months, 1 hour exposure to 100% oxygen at 1.75 ATA
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham treatment - 40 sessions over 2 months, 1 hour exposure to air at 1.3 ATA
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups (HBO2 and sham)
Number of subjects: 75
Study: 10408720

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient management strategies (empathy, emotional support)
Number of subjects: 0
Study: 7675585

Group type: EXPERIMENTAL
Intervention: Bodybuilding program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Aerobics
Number of subjects: 45

Group type: COMPARATOR
Intervention: Circuit training
Number of subjects: 45
Study: 30306805

Group type: EXPERIMENTAL
Intervention: Neurodynamic techniques (20 sessions, twice weekly)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 103
Study: 27220348

Group type: EXPERIMENTAL
Intervention: Tabalumab (120 mg subcutaneously every 2 or 4 weeks)
Number of subjects: 2262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2262
Study: 25218783

Group type: EXPERIMENTAL
Intervention: miravirsen
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 22570325

Group type: EXPERIMENTAL
Intervention: Audiovisual imagery intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study: 19546818

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250 mg/m2 in 20 to 30 minutes) + Cisplatin (75 mg/m2 on day 2)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Gemcitabine (250 mg/m2 in 6 hours infusion) + Cisplatin (75 mg/m2 on day 2)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Gemcitabine (250 mg/m2 in 6 hours infusion) + Cisplatin (75 mg/m2 on day 2) in patients with squamous carcinoma
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 249
Study: 18021337

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 66
Study: 15193818

Group type: EXPERIMENTAL
Intervention: Diet + Simvastatin 20 mg daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Diet (Control)
Number of subjects: 63
Study: 11463131

Group type: EXPERIMENTAL
Intervention: Chewing dextrose tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9874905

Group type: EXPERIMENTAL
Intervention: Enhanced standard methadone maintenance intervention (E‐STD)
Number of subjects: 307

Group type: COMPARATOR
Intervention: High‐intensity, socially demanding day treatment program (DTP)
Number of subjects: 307
Study: 7978377

Group type: EXPERIMENTAL
Intervention: Sperm preparation using immunobeads
Number of subjects: 6
Study: 2926575

Group type: EXPERIMENTAL
Intervention: Spironolactone-hydrochlorothiazide (Aldactazide) at 3 mg/kg/day for 6 to 8 days (n = 12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment (n = 9)
Number of subjects: 21
Study: 4593554

Group type: EXPERIMENTAL
Intervention: Clonidine (25 to 75 mcg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31397866

Group type: EXPERIMENTAL
Intervention: Operative treatment (rotator cuff surgery followed by approximately 4 months of postoperative rehabilitation)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Nonoperative treatment (approximately 3‐month standardized physical therapy program)
Number of subjects: 700
Study: 28244415

Group type: EXPERIMENTAL
Intervention: Liquid honey (10 mL, 4 times a day)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Lozenge honey (10 mL, 4 times a day)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 163
Study: 25529033

Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination therapy of IGU and methotrexate
Number of subjects: 41
Study: 22812912

Group type: EXPERIMENTAL
Intervention: Protocol 1: acid-etching (dentin) + silica coating (composite) + silanization (composite) + primer (dentin) + bonding agent (dentin + composite)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Protocol 2: silica coating (composite) + acid-etching (dentin) + silanization (composite) + primer (dentin) + bonding agent (dentin + composite)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Protocol 3: acid-etching (dentin) + primer (dentin) + silanization (composite) + bonding agent (dentin + composite)
Number of subjects: 72
Study: 21166480

Group type: EXPERIMENTAL
Intervention: Zonisamide 300 mg/day
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Zonisamide 400 mg/day
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Zonisamide (300 and 400 mg/day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 104